PanOptix is already one of the leading presbyopia-correcting IOLs in more than 70 countries. It is designed for today’s active lifestyles, from viewing mobile devices and computer screens to ...
PanOptix, the first and only advanced trifocal lens for U.S. patients undergoing cataract surgery, will be showcased in educational events and clinical data presentations First-ever analyses on IOLs ...
Please provide your email address to receive an email when new articles are posted on . PanOptix, which is already available in more than 70 countries, has been shown to deliver a combination of near, ...
The FINANCIAL — Basel, June 18, 2018 Alcon, the global leader in eye care and a division of Novartis, unveils new data showing significantly improved near and intermediate distance vision with the ...
Please provide your email address to receive an email when new articles are posted on . Patients who received the first FDA-approved trifocal IOL reported high satisfaction with the lens, but some can ...
(RTTNews) - Alcon, a division of Novartis, reported new data showing significantly improved near and intermediate distance vision with the AcrySof IQ PanOptix intraocular lens compared to the ZEISS AT ...
The FINANCIAL — Alcon, one of the global leaders in eye care and a division of Novartis, has received European CE Mark for its AcrySof IQ PanOptix trifocal intraocular lens (IOL) for patients ...
Some might think getting cataract surgery is just one more problem that comes with aging. But Alcon’s introduction of the AcrySof IQ PanOptix Trifocal Lens turns that surgery into a revolutionary ...
GENEVA--(BUSINESS WIRE)-- Alcon, the global leader in eye care dedicated to helping people see brilliantly, today proudly announced that more than 175 million of its intraocular lenses (IOLs) have ...
TORONTO, Nov. 17, 2020 /CNW/ - Alcon, the global leader in eye care, is pleased to announce the Canadian launch of AcrySof ® IQ Vivity ®, a first-of-its-kind, surgical lens designed to help cataract ...
PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses 1,2 More than ninety-nine percent of PanOptix patients in the FDA ...